Jumpstart Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical DevicesColumbus, US
Robert Shalwitz(Executive Officer, Director)inRachael Wingo(Executive Officer)in
BoardWayne Embree(Director)Tim Willis(Director)Faith Voinovich(Director)inBethany George(Director)in
Co-investorsCincyTechJobsOhio VenturesOhio Innovation FundRev1 Ventures
Octet issues hardware-signed cryptographic proofs that a mobile device was physically present in a specified geographic region at a given time, using on-device sensor fusion and secure enclave signing.
CybersecurityEnterprise SoftwareFintech
Co-investorsEx/AnteVariant Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.